Emitof
Generic Name
Ondansetron
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| emitof 8 mg tablet | ৳ 10.00 | ৳ 100.00 |
Description
Overview of the medicine
Emitof 8 mg Tablet contains Ondansetron, which is used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, and surgery.
Uses & Indications
Dosage
Adults
For highly emetogenic chemotherapy: 8 mg orally twice daily, starting 30 minutes before chemotherapy. For moderately emetogenic chemotherapy/radiotherapy: 8 mg orally 1-2 hours before therapy, then 8 mg every 8-12 hours for 1-2 days. For PONV: 8 mg orally one hour before anesthesia or 8 mg 1-2 times daily as needed.
Elderly
No dosage adjustment is generally required for elderly patients. However, caution is advised in patients over 75 years due to potential age-related decrease in renal or hepatic function.
Renal_impairment
No dosage adjustment is required in patients with renal impairment.
How to Take
Emitof tablet should be taken orally with or without food. For prevention of chemotherapy-induced nausea, it should be taken 30 minutes before chemotherapy. For post-operative nausea, it can be taken an hour before anesthesia.
Mechanism of Action
Ondansetron selectively antagonizes 5-HT3 receptors, which are located both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone (CTZ) of the area postrema. By blocking these receptors, it prevents the initiation of the vomiting reflex.
Pharmacokinetics
Onset
Within 30 minutes to 2 hours after oral administration.
Excretion
Approximately 5-10% excreted unchanged in urine, with the remainder excreted as metabolites via both renal and fecal routes.
Half life
Approximately 3-6 hours.
Absorption
Well absorbed from the gastrointestinal tract following oral administration, with peak plasma concentrations occurring within 1.5 to 2 hours.
Metabolism
Extensively metabolized in the liver by cytochrome P450 enzymes (CYP1A2, CYP2D6, CYP3A4).
Side Effects
Contraindications
- •Hypersensitivity to ondansetron or any component of the formulation.
- •Concomitant use of apomorphine (due to risk of profound hypotension and loss of consciousness).
Drug Interactions
Tramadol
Ondansetron may reduce the analgesic effect of tramadol.
Apomorphine
Concomitant use is contraindicated due to reports of profound hypotension and loss of consciousness.
QT-prolonging drugs
Use with caution with other drugs known to prolong the QT interval (e.g., amiodarone, chlorpromazine, quinidine) as it may increase the risk of arrhythmias.
Phenytoin, Carbamazepine, Rifampicin
These enzyme inducers may decrease ondansetron plasma concentrations.
CYP2D6 inhibitors (e.g., Fluoxetine, Paroxetine)
May increase ondansetron plasma concentrations.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include transient vision loss, severe constipation, hypotension, and a vasovagal episode with transient second degree atrioventricular block. Management is symptomatic and supportive, as there is no specific antidote.
Pregnancy & Lactation
Pregnancy Category B. Ondansetron should be used during pregnancy only if clearly needed and the potential benefits outweigh the potential risks to the fetus, especially in the first trimester. Use with caution in nursing mothers, as it is not known whether ondansetron is excreted in human milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months from manufacturing date
Availability
Available in pharmacies nationwide
Approval Status
Approved by major regulatory bodies (e.g., FDA, DGDA)
Patent Status
Off-patent (generic available)
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
